Slide 1: Consolidated Financial Results for H1 2025 and Development Outlook
Consolidated Financial Results for H1 2025 and Development Outlook.
Slide 2: Financial Results – Segment Analysis
Financial Results 3 Segment Analysis Results show a clear change in the revenue structure 3 the growing importance of the generics segment offsets the temporary decline in the innovative segment. Segment 6M24 (PLN m) 6M25 (PLN m) YoY Change Generics (Poland) 69.2 75.4 +9% Generics (Export) 20.8 25.1
Slide 3: Revenue structure by segment (%)
Revenue structure by segment (%) 4.8 16.1 25.1 Generics Domestic Sales Generics Domestic Sales 20.8 Generics Export Generyczne Export Innovations Innovations 69.2 75.4 6M24 6M25 Comparative analysis shows an increase in the share of generics in total revenues from 85% to 95%, with a simultaneous dec
Slide 4: Detailed Group Financial Results
Detailed Group Financial Results Position (PLN Q2-2025 Q2-2024 YoY 6M-2025 6M-2024 YoY 8000) Revenues 56,601 65,611 -14% 105,935 105,945 0% Drug sales 51,076 53,581 -5% 99,648 88,379 +13% Grants 4,742 12,040 -61% 4,757 16,056 -70% Operating costs (73,421) (72,186) +2% (139,104) (130,330) +7% EBIT (1
Slide 5: Generics – Domestic Market - Revenues: PLN 75.4m (+9% YoY)
Generics 3 Domestic Market - Revenues: PLN 75.4m (+9% YoY) Products performance (6M 2024 vs 6M 2025) 30,507 Salmex 29,802 Growth across most 17,766 portfolio products Ketrel 20,209 Improved market 9,984 Zarixa penetration 14,269 4,469 Distribution channel Donepex 5,120 optimization 2,642 Valzek Stro
Slide 6: Generics – Export
Generics 3 Export 25,1 +4,3 24% mln PLN revenues mln PLN share in export within total +20% YoY additional revenues 6M25 revenues Strong Export Performance Development strategy The generics export segment achieved revenues of Maintaining a strong position in foreign markets and PLN 25.1 million, repr
Slide 7: Analysis of the Generics segment
Analysis of the Generics segment Detailed analysis of the results of the generics segment, covering domestic and export sales for H1 2025. Position (PLN 000 . zC) Q2-2025 Q2-2024 Q2 r/r 6M-2025 6M-2024 6M r/r Revenues 51 179 53 571 -4% 100 498 89 889 12% Domestic 39 995 40 762 -2% 75 401 69 087 9% E
Slide 8: Analysis of the R&D Segment Results for H1 2025
Analysis of the R&D Segment Results for H1 2025 Position (000 PLN) Q2-2025 Q2-2024 Q2 r/r 6M-2025 6M-2024 6M r/r Revenues 5 422 12 040 -55% 5 437 16 056 -66% Grants 4 742 12 040 -61% 4 757 16 056 -70% Other Revenues 680 - - 680 - - Operating costs (30 737) (27 391) 12% (56 058) (49 996) 12% External
Slide 9: Innovative Segment – R&D Grants Analysis
Innovative Segment 3 R&D Grants Analysis Revenue decline Revenues from grants: PLN 4.8m vs PLN 16.1m a year earlier (370%) Main Cause: delays in reimbursement processes by institutions financing R&D projects Temporary Nature of the Issues The decline is a timing shift rather than a permanent reducti
Slide 10: Clinical Pipeline – Status
Clinical Pipeline 3 Status CPL9110 (Oncology): Falkieri/Novohale CPL936 (Schizophrenia, Parkinson9s FGFR inhibitor, Phase 1b completed (Neuropsychiatry): dyskinesias): NMDAR agonist/Esketamine, Phase 2 PDE10A inhibitor, Phases 1 & 2 completed, completed, Phase 3 planned late 2025/early advanced part
Slide 11: New Funding Sources
New Funding Sources National Recovery Plan Programme (KPO): TRANSMED I (ABM) 3 4 Signed agreements Grants filed 31,5+ 39 mln zC mln zC Funds allocated to the development of innovative projects The projects focus on the field of translational medicine, and the expansion of the generics portfolio, whi
Slide 12: Financing Strategy for R&D Segment Development
Financing Strategy for R&D Segment Development Diversification of sources Grant competitions Active search for various forms of financing for R&D projects Systematic participation in national and European competitions Reducing dependence on individual grant programs Leveraging the team9s experience
Slide 13: Key Takeaways for the First Half of 2025
Key Takeaways for the First Half of 2025 Group Revenues Generics Growth Innovative grants PLN 105.9m (flat YoY) +9% in Poland, +20% in exports Decline due to reimbursement delays Stable revenue level maintained despite Strong sales dynamics confirming the Temporary in nature 3 normalization challeng